[1]胡雯婧,朱惠娟,龚凤英.脂肪组织衰老与肥胖症关系的研究进展[J].国际内分泌代谢杂志,2023,43(06):492-495.[doi:10.3760/cma.j.cn121383-20220910-09019]
　Hu Wenjing,Zhu Huijuan,Gong Fengying..Research progress of adipose tissue senescence and obesity[J].International Journal of Endocrinology and Metabolism,2023,43(06):492-495.[doi:10.3760/cma.j.cn121383-20220910-09019]
点击复制

脂肪组织衰老与肥胖症关系的研究进展()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
43
期数:
2023年06期
页码:
492-495
栏目:
综述
出版日期:
2023-11-20

文章信息/Info

Title:
Research progress of adipose tissue senescence and obesity
作者:
胡雯婧; 朱惠娟; 龚凤英
中国医学科学院,北京协和医学院,北京协和医院内分泌科,国家卫生健康委员会内分泌重点实验室,协和转化医学中心,北京 100730
Author(s):
Hu Wenjing;  Zhu Huijuan;  Gong Fengying.
Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, the Translational Medicine Center of PUMCH, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing
关键词:
脂肪组织;  细胞衰老;  肥胖症;  衰老相关分泌表型;  抗衰老药物
Keywords:
Adipose tissue;  Cellular senescence;  Obesity;  Senescent-associated secretory phenotypes;  Anti-senescence drug
DOI:
10.3760/cma.j.cn121383-20220910-09019
摘要:
脂肪组织在生物体内主要发挥调节代谢的作用,可以通过感知和储存多余的营养物质来维持糖脂代谢和能量平衡,但年龄的增加和肥胖的发生会削弱脂肪组织对代谢的调节功能。肥胖动物脂肪组织中衰老细胞的发现提示细胞衰老在肥胖的发生发展中起重要作用。脂肪组织包括前脂肪细胞、成熟脂肪细胞、免疫细胞、内皮细胞等多种类型,其中,成熟的脂肪细胞最易衰老。脂肪组织衰老表现为脂肪组织新生障碍、分泌衰老相关分泌表型,进而诱发炎性反应以及全身胰岛素抵抗,加剧肥胖的发生发展。目前研发的抗衰老药物主要是清除衰老细胞和抑制分泌衰老相关分泌表型,通过抗脂肪组织衰老改善肥胖及相关代谢异常成为治疗肥胖的途径。反之,减重亦可以改善脂肪组织的衰老。
Abstract:
Adipose tissue plays a major role in regulating metabolism in living organisms by sensing and storing excess nutrients to maintain glucolipid metabolism and energy balance, however, increasing age and the onset of obesity can diminish the metabolic regulation of adipose tissue. The discovery of senescent cells in the adipose tissue of obese animals has suggested that cellular senescence plays an important role in the development of obesity. Adipose tissue contains a variety of cell types including preadipocytes, mature adipocytes, immune cells and endothelial cells, with mature adipocytes being the most susceptible to senescence. Adipose tissue senescence manifests itself in the form of impaired adipose tissue neogenesis and secretion of senescence-associated secretory phenotypes(SASP), which in turn induces inflammatory responses and systemic insulin resistance, exacerbating the onset and development of obesity. Currently, anti-aging drugs are mainly aimed at removing senescent cells and inhibiting the secretion of SASP, and improving obesity and related metabolic abnormalities through anti-adipose tissue senescence is the way to treat obesity. Conversely, weight-loss can also improve the aging of adipose tissue.

参考文献/References:

[1] Englund D A,Zhang X,Aversa Z,et al. Skeletal muscle aging,cellular senescence,and senotherapeutics: current knowledge and future directions[J].Mech Ageing Dev,2021,200:111595.DOI:10.1016/j.mad.2021.111595.
[2] Cypess AM.Reassessing human adipose tissue[J].N Engl J Med,2022,386(8):768-779.DOI:10.1056/NEJMra2032804.
[3] Palmer AK,Xu M,Zhu Y,et al.Targeting senescent cells alleviates obesity-induced metabolic dysfunction[J].Aging Cell,2019,18(3):e12950.DOI:10.1111/acel.12950.
[4] Di Micco R,Krizhanovsky V,Baker D,et al.Cellular senescence in ageing:from mechanisms to therapeutic opportunities[J].Nat Rev Mol Cell Biol,2021,22(2):75-95.DOI:10.1038/s41580-020-00314-w.
[5] Ou MY,Zhang H,Tan PC,et al.Adipose tissue aging:mechanisms and therapeutic implications[J].Cell Death Dis,2022,13(4):300.DOI:10.1038/s41419-022-04752-6.
[6] Stout MB,Justice JN,Nicklas BJ,et al.Physiological aging:links among adipose tissue dysfunction,diabetes,and frailty[J].Physiology(Bethesda),2017,32(1):9-19.DOI:10.1152/physiol.00012.2016.
[7] Lee G,Kim YY,Jang H,et al.SREBP1c-PARP1 axis tunes anti-senescence activity of adipocytes and ameliorates metabolic imbalance in obesity[J].Cell Metab,2022,34(5):702-718.DOI:10.1016/j.cmet.2022.03.010.
[8] Frasca D,Blomberg BB.Adipose tissue,immune aging,and cellular senescence[J].Semin Immunopathol,2020,42(5):573-587.DOI:10.1007/s00281-020-00812-1.
[9] Smith U,Li Q,Ryden M,et al.Cellular senescence and its role in white adipose tissue[J].Int J Obes(Lond),2021,45(5):934-943.DOI:10.1038/s41366-021-00757-x.
[10] Liu Z,Wu KKL,Jiang X,et al.The role of adipose tissue senescence in obesity- and ageing-related metabolic disorders[J].Clin Sci(Lond),2020,134(2):315-330.DOI:10.1042/CS20190966.
[11] Vergoni B,Cornejo PJ,Gilleron J,et al.DNA damage and the activation of the p53 pathway mediate alterations in metabolic and secretory functions of adipocytes[J].Diabetes,2016,65(10):3062-3074.DOI:10.2337/db16-0014.
[12] Fu W,Liu Y,Sun C,et al.Transient p53 inhibition sensitizes aged white adipose tissue for beige adipocyte recruitment by blocking mitophagy[J].FASEB J,2019,33(1):844-856.DOI:10.1096/fj.201800577R.
[13] Liu Z,Jin L,Yang JK,et al.The dysfunctional MDM2-p53 axis in adipocytes contributes to aging-related metabolic complications by induction of lipodystrophy[J].Diabetes,2018,67(11):2397-2409.DOI:10.2337/db18-0684.
[14] Camell CD,Sander J,Spadaro O,et al.Inflammasome-driven catecholamine catabolism in macrophages blunts lipolysis during ageing[J].Nature,2017,550(7674):119-123.DOI:10.1038/nature24022.
[15] Lee YH,Kim SR,Han DH,et al.Senescent T cells predict the development of hyperglycemia in humans[J].Diabetes,2019,68(1):156-162.DOI:10.2337/db17-1218.
[16] Gustafson B,Nerstedt A,Smith U.Reduced subcutaneous adipogenesis in human hypertrophic obesity is linked to senescent precursor cells[J].Nat Commun,2019,10(1):2757.DOI:10.1038/s41467-019-10688-x.
[17] da Silva PFL,Ogrodnik M,Kucheryavenko O,et al.The bystander effect contributes to the accumulation of senescent cells in vivo[J].Aging Cell,2019,18(1):e12848.DOI:10.1111/acel.12848.
[18] Yang LW,Song M,Li YL,et al.L-Carnitine inhibits the senescence-associated secretory phenotype of aging adipose tissue by JNK/p53 pathway[J].Biogerontology,2019,20(2):203-211.DOI:10.1007/s10522-018-9787-z.
[19] Ehrhardt N,Cui J,Dagdeviren S,et al.Adiposity-independent effects of aging on insulin sensitivity and clearance in mice and humans[J].Obesity(Silver Spring),2019,27(3):434-443.DOI:10.1002/oby.22418.
[20] Wang M,Tan Y,Shi Y,et al.Diabetes and sarcopenic obesity:pathogenesis,diagnosis,and treatments[J].Front Endocrinol(Lausanne),2020,11:568.DOI:10.3389/fendo.2020.00568.
[21] Yi HS,Kim SY,Kim JT,et al.T-cell senescence contributes to abnormal glucose homeostasis in humans and mice[J].Cell Death Dis,2019,10(3):249.DOI:10.1038/s41419-019-1494-4.
[22] Xu M,Pirtskhalava T,Farr JN,et al.Senolytics improve physical function and increase lifespan in old age[J].Nat Med,2018,24(8):1246-1256.DOI:10.1038/s41591-018-0092-9.
[23] De Cecco M,Ito T,Petrashen AP,et al.L1 drives IFN in senescent cells and promotes age-associated inflammation[J].Nature,2019,566(7742):73-78.DOI:10.1038/s41586-018-0784-9.
[24] Li Q,Hagberg CE,Silva Cascales H,et al.Obesity and hyperinsulinemia drive adipocytes to activate a cell cycle program and senesce[J].Nat Med,2021,27(11):1941-1953.DOI:10.1038/s41591-021-01501-8.
[25] Zhang R,Yao K,Chen S,et al.Liraglutide promotes angiogenesis in adipose tissue via suppression of adipocyte-derived IL-6[J].Biochem Biophys Res Commun,2023,651:8-19.DOI:10.1016/j.bbrc.2023.02.007.

相似文献/References:

[1]刘美娟,朱惠娟,龚凤英.Glypican-，4与肥胖及胰岛素抵抗[J].国际内分泌代谢杂志,2015,(03):183.[doi:10.3760/cma.j.issn.1673-4157.2015.03.011]
　Liu Meijuan,Zhu Huijuan,Gong Fengying..Glypican-4 and obesity，insulin resistance[J].International Journal of Endocrinology and Metabolism,2015,(06):183.[doi:10.3760/cma.j.issn.1673-4157.2015.03.011]
[2]李耀辉,侯沃霖,刘芳.肥胖与脂肪组织慢性炎性反应[J].国际内分泌代谢杂志,2016,36(05):342.[doi:10.3760/cma.j.issn.1673-4157.2016.05.15]
　Li Yaohui,Hou Wolin,Liu Fang.Obesity and chronic inflammation in adipose tissue[J].International Journal of Endocrinology and Metabolism,2016,36(06):342.[doi:10.3760/cma.j.issn.1673-4157.2016.05.15]
[3]张娴 陈宏.新型脂肪因子与肥胖相关代谢性疾病[J].国际内分泌代谢杂志,2018,38(03):171.[doi:10.3760/cma.j.issn.1673-4157.2018.03.007]
　Zhang Xian,Chen Hong.Novel adipokines and obesity-related metabolic diseases[J].International Journal of Endocrinology and Metabolism,2018,38(06):171.[doi:10.3760/cma.j.issn.1673-4157.2018.03.007]

备注/Memo

备注/Memo:
基金项目:中国医学科学院医学与健康科技创新工程项目(2022-I2M-2-002); 国家自然科学基金项目(82270913); 北京市自然科学基金(7222137); 国家临床重点专科能力提升项目
通信作者:龚凤英,Email:fygong@sina.com
更新日期/Last Update: 2023-12-30